Thilo  Schroeder net worth and biography

Thilo Schroeder Biography and Net Worth

Director of PMV Pharmaceuticals
Thilo Schroeder, Ph.D. is a Partner at Nextech and has a passion for precision medicines in cancer with a focus on identifying first and best-in-class targeted therapies regardless of drug modality.

Thilo is a board member of Revolution Medicines, PMV Pharma, IDEAYA Biosciences (NASDAQ: IDYA), ImaginAb and is a board observer of Black Diamond Therapeutics. Past board seats include Blueprint Medicines (NASDAQ: BPMC) and Peloton Therapeutics (acquired by Merck).

Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology developed by Molecular Partners (SWX:MOLN).

What is Thilo Schroeder's net worth?

The estimated net worth of Thilo Schroeder is at least $2.87 million as of December 5th, 2024. Mr. Schroeder owns 2,096,612 shares of PMV Pharmaceuticals stock worth more than $2,872,358 as of January 20th. This net worth estimate does not reflect any other assets that Mr. Schroeder may own. Learn More about Thilo Schroeder's net worth.

How do I contact Thilo Schroeder?

The corporate mailing address for Mr. Schroeder and other PMV Pharmaceuticals executives is , , . PMV Pharmaceuticals can also be reached via phone at 609-642-6670 and via email at investors@pmvpharma.com. Learn More on Thilo Schroeder's contact information.

Has Thilo Schroeder been buying or selling shares of PMV Pharmaceuticals?

Thilo Schroeder has not been actively trading shares of PMV Pharmaceuticals during the last quarter. Most recently, Thilo Schroeder sold 800 shares of the business's stock in a transaction on Wednesday, October 6th. The shares were sold at an average price of $30.15, for a transaction totalling $24,120.00. Learn More on Thilo Schroeder's trading history.

Who are PMV Pharmaceuticals' active insiders?

PMV Pharmaceuticals' insider roster includes Leila Alland (Insider), Richard Heyman (Director), Winston Kung (CFO), Arnold Levine (Director), David Mack (CEO), and Thilo Schroeder (Director). Learn More on PMV Pharmaceuticals' active insiders.

Are insiders buying or selling shares of PMV Pharmaceuticals?

During the last twelve months, insiders at the sold shares 2 times. They sold a total of 10,109 shares worth more than $15,163.50. The most recent insider tranaction occured on September, 11th when insider Deepika Jalota sold 7,218 shares worth more than $10,827.00. Insiders at PMV Pharmaceuticals own 7.6% of the company. Learn More about insider trades at PMV Pharmaceuticals.

Information on this page was last updated on 9/11/2024.

Thilo Schroeder Insider Trading History at PMV Pharmaceuticals

Thilo Schroeder Buying and Selling Activity at PMV Pharmaceuticals

This chart shows Thilo Schroeder's buying and selling at PMV Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total Insider BuyingTotal Insider Selling

PMV Pharmaceuticals Company Overview

PMV Pharmaceuticals logo
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Read More

Today's Range

Now: $1.37
Low: $1.36
High: $1.40

50 Day Range

MA: $1.54
Low: $1.35
High: $1.69

2 Week Range

Now: $1.37
Low: $1.32
High: $2.26

Volume

59,171 shs

Average Volume

131,073 shs

Market Capitalization

$70.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46